Sana Biotechnology (SANA) Interest Expenses (2020 - 2026)
Sana Biotechnology (SANA) posted Interest Expenses of $113.8 million for Q1 2026, up 11377100.0% sequentially from $1000.0 in Q4 2025, and down 31.62% YoY from $166.4 million in Q1 2025.
Sana Biotechnology (SANA) Interest Expenses (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Interest Expenses for 7 years, with the latest figure at $113.8 million in Q1 2026.
- Quarterly Interest Expenses fell 31.62% year-over-year to $113.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.8 million (down 31.62% YoY) and the FY2025 annual result came in at $119.3 million, up 53.81% from the prior year.
- Interest Expenses improved to $113.8 million in Q1 2026 per SANA's latest filing, from $1000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $402.7 million in Q4 2023 and troughed at $1000.0 in Q4 2025.
- A 5-year average of $127.1 million and a median of $113.8 million in 2026 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses surged 10750.42% in 2023, then slumped 99.93% in 2025.
- Over 5 years, Interest Expenses stood at $3.7 million in 2022, then soared by 10750.42% to $402.7 million in 2023, then slumped by 99.63% to $1.5 million in 2024, then plunged by 99.93% to $1000.0 in 2025, then surged by 11377100.0% to $113.8 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $113.8 million, $1000.0, and $42.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | 110.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.60 Mn |
| Jun 30, 2026 | 110.60 Mn |
| Mar 31, 2026 | 113.77 Mn |
| Mar 31, 2026 | 113.77 Mn |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 42.59 Mn |
| Sep 30, 2025 | 42.59 Mn |
| Jun 30, 2025 | 130.28 Mn |
| Jun 30, 2025 | 130.28 Mn |
| Mar 31, 2025 | 166.39 Mn |
| Mar 31, 2025 | 166.39 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 176.43 Mn |
| Sep 30, 2024 | 176.43 Mn |
| Jun 30, 2024 | 83.00 Mn |
| Jun 30, 2024 | 83.00 Mn |
| Mar 31, 2024 | 85.98 Mn |
| Mar 31, 2024 | 85.98 Mn |